India Flags Safety Concerns Over Two Widely Used Medicines: What Doctors and Patients Must Know

In a significant move aimed at strengthening public health safeguards, India’s drug safety authority has issued a fresh alert concerning two commonly prescribed medications—Tranexamic Acid and Metoclopramide. The advisory, released by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health & Family Welfare, follows a detailed analysis of adverse drug reactions reported in August 2025 under the Pharmacovigilance Programme of India (PvPI). Here’s a comprehensive breakdown of what the alert entails, why it matters, and what steps stakeholders should take.

Background: What Triggered the Alert  
1. The IPC’s safety notice stems from recent data collected through PvPI, India’s national drug monitoring system  
2. The alert is part of a routine pharmacovigilance effort to identify and mitigate risks associated with widely consumed medications  
3. The two drugs flagged—Tranexamic Acid and Metoclopramide—are used across hospitals, clinics, and homes for treating bleeding disorders and gastrointestinal issues respectively  
4. The IPC has urged healthcare professionals and patients to monitor for specific adverse reactions and report them promptly

Tranexamic Acid: Used for Bleeding Control  
Tranexamic Acid is prescribed to manage excessive bleeding in conditions such as heavy menstrual flow (menorrhagia), nosebleeds, and post-operative recovery. While generally considered safe, the IPC has flagged a new concern:

- Key highlight: Nasal congestion has emerged as a notable side effect  
- Though not life-threatening, persistent congestion can cause discomfort and may signal deeper complications  
- Doctors are advised to assess patient history and monitor symptoms closely, especially in cases of prolonged use  
- The drug’s global market is projected to cross 100 million dollars by 2029, indicating its widespread use and relevance

Metoclopramide: A Common GI Medication  
Metoclopramide is widely used to treat nausea, vomiting, heartburn, and gastro-duodenal dysfunction. It is often prescribed in emergency rooms and general practice settings. The IPC’s alert draws attention to a potentially serious cardiac side effect:

- Key concern: Tachycardia, or rapid heart rate, has been linked to Metoclopramide use  
- While tachycardia can be benign in some cases, drug-induced episodes may lead to complications such as stroke or heart failure if left unchecked  
- Physicians are urged to evaluate cardiovascular risk before prescribing and to educate patients on early warning signs  
- The global market for Metoclopramide was valued at over 1.5 billion dollars in 2024, underscoring its widespread consumption

Implications for Healthcare Providers  
- Doctors should update patient records with any reported adverse reactions and consider alternative therapies when necessary  
- Pharmacists must ensure that patients are informed about potential side effects at the point of sale  
- Hospitals and clinics are encouraged to participate actively in PvPI by reporting ADRs through official channels  
- Medical colleges have been directed to establish adverse event committees in coordination with IPC to improve vigilance

Guidance for Patients and Caregivers  
- Patients currently using either medication should not discontinue use abruptly but consult their physician if symptoms arise  
- Awareness of side effects like nasal congestion or rapid heartbeat is crucial for early intervention  
- Caregivers should monitor vulnerable populations such as the elderly and those with pre-existing conditions more closely  
- Reporting suspected ADRs to the nearest healthcare facility or through PvPI’s online portal can contribute to safer drug practices

Looking Ahead: Strengthening India’s Drug Safety Net  
This alert is part of a broader initiative by the IPC and CDSCO to enhance pharmacovigilance and ensure safer medication practices across India. With drug trials and exports on the rise, such alerts play a vital role in maintaining public trust and regulatory integrity. The IPC continues to analyze real-time data and collaborate with global agencies to align India’s drug safety standards with international benchmarks.

Source: LiveMint, Indian Pharmacopoeia Commission